1. Home
  2. AIIR vs WVE Comparison

AIIR vs WVE Comparison

Compare AIIR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIIR

Air Global PLC Ordinary Shares

N/A

Current Price

$6.07

Market Cap

1.1B

ML Signal

N/A

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.04

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIIR
WVE
Founded
N/A
2012
Country
United Arab Emirates
Singapore
Employees
N/A
317
Industry
Tobacco
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
AIIR
WVE
Price
$6.07
$6.04
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$29.81
AVG Volume (30 Days)
10.0K
2.2M
Earning Date
N/A
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$85.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$5.29
$5.02
52 Week High
$8.15
$21.73

Technical Indicators

Market Signals
Indicator
AIIR
WVE
Relative Strength Index (RSI) 46.13 53.05
Support Level $5.29 $5.49
Resistance Level $6.62 $6.21
Average True Range (ATR) 0.67 0.25
MACD 0.03 0.03
Stochastic Oscillator 38.36 83.54

Price Performance

Historical Comparison
AIIR
WVE

About AIIR Air Global PLC Ordinary Shares

AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: